주)티씨노바이오사이언스는 저분자 혁신항암제(표적항암제/면역항암제) 파이프라인과 선천면역항암제 평가기술인 LIN/TMED, Kinase 저해제 평가기술인 Ba/F3 평가계 등의 핵심 플랫폼 기술을 확보 및 구축하여 2020년에 9월에 설립한 KIST 기술출자 바이오 벤처입니다. 현재 RAS 관련 표적항암제 3개의 파이프라인과 선천면역항암제 2개의 파이프라인을 연구 개발 중입니다.
Company Details
- Employees
- 15
- Founded
- -
- Address
- 수지구 광교중앙로 338, (상현동,광교우미뉴브) C동 707호,korea, Republic Of
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.txinno.com
- Keywords
- 저분자 약물 개발, 혁신항암제, 선천면역항암제, RAS 변이 항암제, LIN, Ba/F3, TMED.
- HQ
- 용인, 경기도
Txinno Bioscience Inc Questions
Txinno Bioscience Inc's website is http://www.txinno.com
Txinno Bioscience Inc's LinkedIn profile is https://kr.linkedin.com/company/txinno-bioscience-inc
Txinno Bioscience Inc has
15 employees.
View email and phone details for 15
employees at Txinno Bioscience Inc.
Txinno Bioscience Inc's industry is
Pharmaceutical Manufacturing
Txinno Bioscience Inc's top competitors are
Hme Square,
Insilico Medicine,
Rokit Genomics,
Johnson & Johnson,
Avelos Therapeutics,
Pin Therapeutics, Inc.,
Advanced Comprehensive Laboratory,
스위스아미에트(주),
Al,
St Pharm.
Txinno Bioscience Inc's categories are Pharmaceutical Manufacturing
Txinno Bioscience Inc's founding year is 2020
